Ardelyx (ARDX)
(Real Time Quote from BATS)
$4.37 USD
+0.04 (0.92%)
Updated Aug 4, 2025 11:44 AM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARDX 4.37 +0.04(0.92%)
Will ARDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDX
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
ARDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for ARDX
Here are the major earnings after the close Monday
Earnings Scheduled For August 4, 2025
Ardelyx (ARDX) to Report Q2 Earnings: What Investors Can Expect
Ardelyx Q2 2025 Earnings Preview
Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying